Balance Sheet

Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

SOPHiA GENETICS (SOPH) Amortization (2020)

SOPHiA GENETICS's Amortization history spans 1 years, with the latest figure at $3.3 billion for Q4 2020.

On a quarterly basis, Amortization changed N/A to $3.3 billion in Q4 2020 year-over-year; TTM through Dec 2020 was $3.3 billion, a N/A change, with the full-year FY2020 number at $3.3 billion, changed N/A from a year prior.
Amortization hit $3.3 billion in Q4 2020 for SOPHiA GENETICS.
Over the last five years, Amortization for SOPH hit a ceiling of $3.3 billion in Q4 2020 and a floor of $3.3 billion in Q4 2020.